CD155 Antibody Market, Global Outlook and Forecast 2025-2032

MARKET INSIGHTS

The global CD155 Antibody market was valued at USD 450 million in 2024 and is projected to reach USD 1066 million by 2032, exhibiting a compound annual growth rate (CAGR) of 13.4% during the forecast period. This significant growth trajectory reflects increasing research applications in oncology and immunotherapy.

CD155 Antibody is a specialized immunological reagent targeting the CD155 protein, also known as Poliovirus Receptor (PVR) or Necl-5. This cell surface molecule belongs to the immunoglobulin superfamily and plays critical roles in cellular adhesion, immune regulation, and tumor microenvironment interactions. The antibody finds extensive use in research applications including flow cytometry, Western blotting, and immunofluorescence studies.

Market expansion is driven by several key factors: rising cancer research investments, growing demand for immune checkpoint inhibitors, and increasing prevalence of autoimmune disorders. Furthermore, the antibody's emerging therapeutic potential in cancer immunotherapy - particularly its role in modulating T-cell and NK-cell activity - is creating new opportunities. Major industry players like Abcam, Sino Biological, and Bio-Techne are actively developing advanced CD155 antibody products to meet this growing demand, contributing to market dynamism.

MARKET DYNAMICS

MARKET DRIVERS

Rising Prevalence of Cancer and Autoimmune Diseases to Propel CD155 Antibody Demand

The global increase in cancer incidence and autoimmune disorders is driving substantial growth in the CD155 antibody market. CD155 plays a critical role in tumor immune evasion mechanisms and has been identified as a promising target for cancer immunotherapy. With over 19 million new cancer cases diagnosed annually worldwide, research into immune checkpoint inhibitors addressing CD155 pathways has intensified. The antibody's application in studying tumor microenvironments and developing T-cell engaging therapies positions it as a valuable tool for oncological research and therapeutic development.

Advancements in Immunotherapy Research Accelerating Market Expansion

Breakthroughs in immunotherapy, particularly immune checkpoint inhibition therapies, are creating significant demand for CD155 antibodies. The growing understanding of CD155's interaction with DNAM-1 and TIGIT receptors has made it a focal point for novel immunotherapy development. Pharmaceutical companies are increasingly investing in CD155-related research, with several clinical trials currently investigating antibodies targeting the CD155 pathway. The global immunotherapy market, projected to exceed $300 billion by 2030, provides a robust foundation for CD155 antibody growth as researchers seek to uncover new therapeutic targets.

➤ Recent studies demonstrate that CD155 expression correlates with poor prognosis in multiple cancer types, making it a high-value target for both diagnostic and therapeutic applications.

Furthermore, increased funding for immune-oncology research from both public and private sectors is accelerating the development and commercialization of CD155 antibodies, with the market expected to maintain double-digit growth throughout the forecast period.

MARKET RESTRAINTS

High Development Costs and Technical Complexities Restraining Market Penetration

The production of high-quality CD155 antibodies presents significant technical challenges that constrain market growth. Antibody development requires specialized expertise in protein engineering and immunology, with success rates for functional antibody generation remaining below 30% in many cases. The complex tertiary structure of CD155 and its glycosylation patterns make antibody development particularly challenging, requiring sophisticated purification and validation processes that substantially increase production costs.

Regulatory Hurdles and Validation Requirements Slowing Adoption

Stringent regulatory requirements for antibody validation in research and diagnostic applications create additional barriers to market expansion. Many research institutions and pharmaceutical companies require extensive validation data before adopting new antibodies, with batch-to-batch consistency being a particular concern. The lack of standardized validation protocols for CD155 antibodies across different applications (flow cytometry, immunohistochemistry, etc.) further complicates the commercialization process, potentially delaying research progress and therapeutic development timelines.

MARKET CHALLENGES

Antibody Specificity and Cross-Reactivity Issues Creating Research Bottlenecks

A major challenge facing the CD155 antibody market is ensuring antibody specificity given the structural similarities within the immunoglobulin superfamily. Many commercially available antibodies demonstrate unwanted cross-reactivity with related proteins, potentially compromising research results. This issue is particularly problematic in translational research where accurate target identification is critical. Reported instances of inconsistent performance between monoclonal and polyclonal CD155 antibody preparations have led some researchers to conduct extensive in-house validation, adding time and cost to experimental workflows.

Additional Challenges

Limited Commercial Availability for Certain Applications
Many researchers report difficulties finding CD155 antibodies validated for specific applications such as chromatin immunoprecipitation (ChIP) or super-resolution microscopy, limiting experimental possibilities.

Storage and Stability Concerns
The fragile nature of some antibody formulations leads to stability issues during shipping and storage, particularly affecting international distribution to emerging research markets where cold chain infrastructure may be inconsistent.

MARKET OPPORTUNITIES

Expansion into Companion Diagnostics Creating New Revenue Streams

The growing field of companion diagnostics presents significant opportunities for CD155 antibody developers. As CD155-targeted therapies advance through clinical trials, the need for reliable diagnostic antibodies to identify patient populations likely to respond to treatment will increase. The companion diagnostics market is projected to grow at over 12% annually, with oncology applications representing the largest segment. CD155 antibody providers that can demonstrate clinical-grade consistency and reproducibility stand to benefit from long-term partnerships with pharmaceutical companies developing CD155-targeted immunotherapies.

Emerging Markets and Academic Research Partnerships Offering Growth Potential

Increasing life science research funding in Asia-Pacific countries is creating new opportunities for CD155 antibody suppliers. Countries like China and India are rapidly expanding their biomedical research capabilities, with government initiatives supporting local antibody production and international collaborations. Strategic partnerships between antibody manufacturers and academic institutions can accelerate product development while providing researchers with customized solutions. Additionally, the trend toward open innovation models in pharmaceutical research is fostering new opportunities for antibody providers to participate in consortiums focused on immune checkpoint discovery and validation.

Segment Analysis:

By Type

Monoclonal Antibody Segment Leads Due to High Specificity in Research and Diagnostic Applications

The market is segmented based on type into:

• Monoclonal Antibody

• Polyclonal Antibody

By Application

Flow Cytometry Dominates Due to Widespread Use in Immune Cell Analysis and Cancer Research

The market is segmented based on application into:

• Flow Cytometry

• ELISA

• Western Blot

• Immunoprecipitation

• Immunofluorescence

• Others

By End User

Academic & Research Institutions Account for Significant Adoption Due to Growing Cancer Biology Studies

The market is segmented based on end user into:

• Pharmaceutical & Biotechnology Companies

• Academic & Research Institutions

• Diagnostic Laboratories

• Contract Research Organizations

COMPETITIVE LANDSCAPE

Key Industry Players

Innovation and Strategic Collaborations Drive Market Competition

The global CD155 antibody market features a dynamic competitive landscape with both established players and emerging biotech companies vying for market share. As of 2024, the market remains semi-consolidated, with the top five companies collectively holding approximately 42% of total revenue share. While monoclonal antibodies dominate the product segment (holding 68% share), polyclonal antibodies are gaining traction in research applications due to their broader epitope recognition.

Sino Biological, Inc. and Abcam currently lead the market through their extensive antibody portfolios and strong distribution networks across North America and Europe. Both companies have recently expanded their CD155 antibody offerings, with Sino Biological launching three new recombinant monoclonal antibodies in Q1 2024. Their growth stems from increasing demand in cancer immunotherapy research, where CD155's role in immune checkpoint regulation is being actively studied.

Mid-sized players like Cell Signaling Technology, Inc. and Bio-Techne are making significant strides through technological differentiation. Cell Signaling's recent development of a propriety CD155 antibody validation protocol has strengthened its position in academic research markets. Meanwhile, Bio-Techne's acquisition of a smaller antibody manufacturer in late 2023 expanded its production capacity by 35%, enabling faster delivery times in key Asian markets.

Emerging Trends and Strategic Moves

Several noteworthy trends are shaping competitive dynamics:

• Increasing R&D investments in therapeutic antibody development targeting CD155 pathways
• Strategic partnerships between antibody producers and diagnostic equipment manufacturers
• Expansion into emerging APAC markets with localized production facilities

Creative Biolabs and GeneTex have particularly benefited from these trends, reporting 28% and 19% revenue growth respectively in 2023. Their success stems from focusing on high-growth applications like immunofluorescence and flow cytometry while maintaining rigorous quality standards demanded by pharmaceutical clients.

List of Key CD155 Antibody Companies Profiled

• Sino Biological, Inc. (China)
• Abcam (UK)
• Cell Signaling Technology, Inc. (U.S.)
• Bio-Techne (U.S.)
• Assay Genie (Ireland)
• MyBiosource, Inc. (U.S.)
• Biorbyt (UK)
• Creative Biolabs (U.S.)
• GeneTex (U.S.)
• Arigo Biolaboratories Corp. (Taiwan)

CD155 ANTIBODY MARKET TRENDS

Immunotherapy Advancements Fueling CD155 Antibody Market Growth

The global CD155 antibody market is experiencing significant momentum due to breakthroughs in immunotherapy research, particularly in cancer treatment applications. CD155 (Poliovirus Receptor) has emerged as a critical immune checkpoint molecule, with monoclonal antibodies targeting this protein showing promising results in clinical trials. Recent studies indicate that CD155 blockade enhances T-cell and natural killer (NK) cell-mediated tumor killing, with preclinical models demonstrating up to 60% reduction in metastatic spread when combined with existing immunotherapies. Pharmaceutical companies are increasingly investing in this space, with five new CD155-related drug candidates entering phase I/II trials in 2023 alone. This therapeutic potential is accelerating demand for high-quality research antibodies across both academic institutions and biopharma R&D departments.

Other Trends

Multiplex Biomarker Analysis Driving Adoption

The shift toward multiplex immunoassay platforms is creating robust demand for CD155 antibodies validated for simultaneous target detection. Flow cytometry panels incorporating CD155 analysis grew by 28% year-over-year in core research facilities, as scientists seek to understand its co-expression patterns with other immune checkpoints like PD-1 and CTLA-4. This trend aligns with broader movements in precision oncology, where comprehensive immune profiling requires antibodies with proven specificity in complex assay environments. Manufacturers are responding with antibody pairs pre-conjugated to distinct fluorophores and validation data across multiple platforms including mass cytometry and spectral flow.

Technological Improvements in Antibody Production

Innovations in recombinant antibody engineering are addressing longstanding challenges in CD155 research. While traditional polyclonal preparations showed batch-to-batch variability exceeding 15%, next-generation recombinant monoclonal antibodies now achieve lot consistency below 5% variation while maintaining high affinity (KD < 1nM). Furthermore, new labeling techniques enable site-specific conjugation without affecting antigen binding - a critical advancement for quantitative applications. These technological improvements are reducing experimental variables and reproducibility concerns that previously hampered CD155 research, particularly in longitudinal studies requiring standardized reagents over extended periods.

Regional Analysis: CD155 Antibody Market

North America
The North American CD155 Antibody market is experiencing robust growth, driven by substantial biotechnology R&D investments and a well-established healthcare infrastructure. The U.S. holds the largest share in the region, accounting for over 80% of revenue, with major academic institutions and pharmaceutical companies actively researching CD155's role in immunotherapy. Recent FDA approvals for immune checkpoint inhibitors have further accelerated demand for CD155 antibodies as potential complementary therapeutics. Canadian research initiatives focusing on tumor microenvironment studies also contribute to market expansion. However, stringent regulatory pathways and high product development costs present challenges for smaller biotech firms.

Europe
Europe maintains a strong position in the CD155 Antibody market, characterized by collaborative research networks and increasing oncology research funding. Germany and the U.K. lead in adoption, with their advanced life sciences sectors investing heavily in antibody-based research tools. The European Medicines Agency's evolving guidelines for biologics have prompted manufacturers to enhance antibody validation standards. While Western Europe shows mature market characteristics, Eastern European countries are emerging as growth hotspots due to expanding biotech capabilities and lower operational costs. The region's focus on translational research bridging basic science and clinical applications creates sustained demand for high-quality research antibodies.

Asia-Pacific
Asia-Pacific represents the fastest-growing CD155 Antibody market, projected to achieve a 16.8% CAGR through 2030. China dominates regional consumption, propelled by government-backed biopharma initiatives and increasing cancer research expenditure. Japan follows closely, with its strong antibody production capabilities and aging population driving oncology research. India's market is expanding through cost-effective antibody production and growing contract research organizations. While price sensitivity remains a factor, the region benefits from lower manufacturing costs and expanding academic-industry collaborations. Emerging applications in infectious disease research, particularly post-pandemic, are creating new growth avenues across Southeast Asian countries.

South America
The South American CD155 Antibody market shows gradual but steady growth, with Brazil and Argentina accounting for 75% of regional demand. Increasing cancer prevalence and improving research infrastructure support market development, though economic constraints limit widespread adoption. Local manufacturers are gaining traction by offering affordable alternatives to imported antibodies. Collaborative projects between regional research centers and global pharmaceutical companies are enhancing technical capabilities. The market faces challenges including currency volatility and fragmented distribution networks, but rising government support for life sciences presents future opportunities.

Middle East & Africa
This region exhibits nascent but promising growth in the CD155 Antibody market, with Israel, Saudi Arabia, and South Africa as key markets. Increased healthcare investments and growing awareness of precision medicine drive demand, though the market remains import-dependent. Dubai's emerging biotech hub status attracts global antibody suppliers, while local universities are building research capacity. Africa shows potential through international health initiatives focused on infectious diseases, where CD155 research gains relevance. Infrastructure limitations and lack of specialized cold chain logistics currently hinder market expansion, but strategic partnerships aim to overcome these barriers.

Report Scope

This market research report offers a holistic overview of global and regional CD155 Antibody markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.

Key Coverage Areas:

• ✅ Market Overview

  • Global and regional market size (historical & forecast)

  • Growth trends and value/volume projections

• ✅ Segmentation Analysis

  • By product type or category

  • By application or usage area

  • By end-user industry

  • By distribution channel (if applicable)

• ✅ Regional Insights

  • North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

  • Country-level data for key markets

• ✅ Competitive Landscape

  • Company profiles and market share analysis

  • Key strategies: M&A, partnerships, expansions

  • Product portfolio and pricing strategies

• ✅ Technology & Innovation

  • Emerging technologies and R&D trends

  • Automation, digitalization, sustainability initiatives

  • Impact of AI, IoT, or other disruptors (where applicable)

• ✅ Market Dynamics

  • Key drivers supporting market growth

  • Restraints and potential risk factors

  • Supply chain trends and challenges

• ✅ Opportunities & Recommendations

  • High-growth segments

  • Investment hotspots

  • Strategic suggestions for stakeholders

• ✅ Stakeholder Insights

  • Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers

FREQUENTLY ASKED QUESTIONS:

What is the current market size of Global CD155 Antibody Market?

-> The global CD155 Antibody market was valued at USD 450 million in 2024 and is projected to reach USD 1066 million by 2032, growing at a CAGR of 13.4%.

Which key companies operate in Global CD155 Antibody Market?

-> Key players include Sino Biological, Inc., Abcam, Assay Genie, Cell Signaling Technology, Inc., MyBiosource, Inc., Biorbyt, Creative Biolabs, GeneTex, Arigo Biolaboratories Corp., and RayBiotech, Inc., among others.

What are the key growth drivers?

-> Key growth drivers include rising cancer research activities, increasing demand for immunotherapy, and growing focus on autoimmune disease treatment.

Which region dominates the market?

-> North America holds the largest market share, while Asia-Pacific is expected to witness the highest growth rate.

What are the emerging trends?

-> Emerging trends include development of novel monoclonal antibodies, increasing adoption in precision medicine, and advancements in antibody engineering technologies.